Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q2 2021 · 10-Q
Revenue—
Net Income-$649.86K-$649.86KN/M vs Q2 2020 EPS Diluted-$0.02-$0.02N/M vs Q2 2020 Operating Income-$441,818N/M Operating Cash Flowderived-$407,110N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Free Cash Flowderived-$407,110— ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end